Iminodiacetic Acid as a Novel Metal‐Binding Pharmacophore for New Delhi Metallo‐β‐lactamase Inhibitor Development
作者:Allie Y. Chen、Caitlyn A. Thomas、Pei W. Thomas、Kundi Yang、Zishuo Cheng、Walter Fast、Michael W. Crowder、Seth M. Cohen
DOI:10.1002/cmdc.202000123
日期:2020.7.20
metallo‐β‐lactamase‐1 (NDM‐1) that inhibits by removing ZnII from the active‐site. The nonselective metal‐chelating properties and difficult synthesis and derivatization of AMA have hindered the development of this scaffold into a potent and selective inhibitor of NDM‐1. Iminodiacetic acid (IDA) has been identified as the metal‐binding pharmacophore (MBP) core of AMA that can be leveraged for inhibitor
真菌天然产物曲霉菌素 A (AMA) 已被鉴定为新德里金属-β-内酰胺酶-1 (NDM-1) 的非竞争性抑制剂,通过从活性位点去除 Zn II来抑制。 AMA 的非选择性金属螯合特性以及合成和衍生化的困难阻碍了该支架发展成为有效的选择性 NDM-1 抑制剂。亚氨基二乙酸 (IDA) 已被确定为 AMA 的金属结合药效团 (MBP) 核心,可用于抑制剂开发。在此,我们报告了 IDA 用于 NDM-1 抑制剂的基于片段的药物发现 (FBDD)。 IDA (IC 50 =120 μM) 被开发成抑制剂23 f (IC 50 =8.6 μM , Ki = 2.6 μM),它与 NDM-1 形成三元复合物,由蛋白质热位移和天然态电喷雾证明电离质谱(ESI-MS)实验。将机制分析与抑制剂衍生化相结合,详细介绍了使用 IDA 作为 NDM-1 抑制剂开发的替代 AMA 支架。